JP2015120650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015120650A5 JP2015120650A5 JP2013264454A JP2013264454A JP2015120650A5 JP 2015120650 A5 JP2015120650 A5 JP 2015120650A5 JP 2013264454 A JP2013264454 A JP 2013264454A JP 2013264454 A JP2013264454 A JP 2013264454A JP 2015120650 A5 JP2015120650 A5 JP 2015120650A5
- Authority
- JP
- Japan
- Prior art keywords
- attachment
- therapeutic agent
- agent according
- preparation
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 101710008205 OXT Proteins 0.000 claims 2
- 102100017240 OXT Human genes 0.000 claims 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N Oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims 2
- 229960001723 Oxytocin Drugs 0.000 claims 2
- 101700057139 oxyT Proteins 0.000 claims 2
- 230000000699 topical Effects 0.000 claims 2
- 206010014551 Emotional disease Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001058 adult Effects 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007923 nasal drop Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013264454A JP6304744B2 (ja) | 2013-12-20 | 2013-12-20 | 愛着障害治療剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013264454A JP6304744B2 (ja) | 2013-12-20 | 2013-12-20 | 愛着障害治療剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015120650A JP2015120650A (ja) | 2015-07-02 |
| JP2015120650A5 true JP2015120650A5 (pl) | 2016-12-15 |
| JP6304744B2 JP6304744B2 (ja) | 2018-04-04 |
Family
ID=53532654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013264454A Active JP6304744B2 (ja) | 2013-12-20 | 2013-12-20 | 愛着障害治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6304744B2 (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3369429B1 (en) * | 2015-10-30 | 2019-12-11 | Teijin Pharma Limited | Pharmaceutical composition intended to be administered to nasal mucosa |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2500831A1 (en) * | 2002-10-03 | 2004-04-15 | Eric Hollander | Treatment of autism and similar disorders |
-
2013
- 2013-12-20 JP JP2013264454A patent/JP6304744B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| JP2015057451A5 (pl) | ||
| JP2016147915A5 (pl) | ||
| SG11201804449WA (en) | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| WO2017091749A8 (en) | Shape changing drug delivery devices and methods | |
| EP3308785A3 (en) | Use of flecainide as an anti-connexin agent and method for potentiating the effects of a psychotropic drug | |
| IN2014DN09434A (pl) | ||
| EP3682875A3 (en) | Methods of treating pediatric metabolic syndrome | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| JP2015523407A5 (pl) | ||
| IL232764A (en) | Fluoromethyl6,5 - Dihydro - 4 H - [3,1] Oxazines, Pharmaceuticals Containing Them and Their Use in the Preparation of Medicines to Treat Alzheimer's Disease | |
| EP3300734A3 (en) | Use of levocetirizine and montelukast in the treatment of autoimmune disorders | |
| PH12020500543A1 (en) | Nonracemic mixtures and uses thereof | |
| CU20190060A7 (es) | Formas de administración farmacéutica que contienen inhibidores de canales task-1 y task-3 útiles en el tratamiento de trastornos respiratorios | |
| MY165888A (en) | Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation | |
| JP2015522522A5 (pl) | ||
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| JP2011190199A5 (pl) | ||
| EA201500513A1 (ru) | Продукт сомикронизации, включающий ацетат улипристала | |
| WO2015009731A3 (en) | Azacyclic constrained analogs of fty720 | |
| JP2013533867A5 (pl) | ||
| BR112016007238A2 (pt) | tienouracilcarboxamidas cíclicas e sua utilização | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| JP2017061488A5 (pl) |